News & Events
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Crinetics Pharmaceuticals management will present a corporate overview at the H. C. Wainwright 24th Annual Global Investment Conference on September 12, 2022
READ MORENew Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
Two-year data from Advance OLE acromegaly study shows maintenance of IGF-1 and preference for paltusotine over injected SRLs
READ MORENew Long-Term Safety and Efficacy Data for Paltusotine to be Presented at CBEM
New safety and efficacy data from a two-year interim analysis from the ACROBAT Advance study will be presented at the 35th Brazilian Congress of Endocrinology and Metabolism
READ MORECrinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Crinetics reported financial results for the second quarter ended June 30, 2022 and provided an update on paltusotine's Phase 3 program in acromegaly and Phase 2 in carcinoid syndrome, as well as plans to advance CRN04894 and CRN04777.
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces August 2022 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces July 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MOREAdditional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
Crinetics VP of clinical endocrinology, Peter J. Trainer, M. D.
READ MORECrinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces June 2022 inducement grants: the stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
READ MORECrinetics Presents Clinical and Research Results at ENDO 2022
Crinetics Pharmaceuticals to present findings from Phase 1 programs of CRN04894 and CRN04777 as well as discovery of PTHR1 antagonist at ENDO 2022.
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
